TBB | Tetrabromobenzotriazole | CAS#17374-26-4 | CK2 Inhibitor

MedKoo Cat#: 406400 | Name: Tetrabromobenzotriazole

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tetrabromobenzotriazole, also known as TBB and NSC231634, is a potent protein kinase CK2 inhibitor, which induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells.

Chemical Structure

Tetrabromobenzotriazole

CAS#17374-26-4

Theoretical Analysis

MedKoo Cat#: 406400

Name: Tetrabromobenzotriazole

CAS#: 17374-26-4

Chemical Formula: C6HBr4N3

Exact Mass: 430.6904

Molecular Weight: 434.71

Elemental Analysis: C, 16.58; H, 0.23; Br, 73.52; N, 9.67

Price and Availability

Size	Price	Availability
10mg	USD 350.00
25mg	USD 550.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TBB, Tetrabromobenzotriazole, NSC 231634, NSC231634, NSC-231634

IUPAC/Chemical Name

4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole

InChi Key

OMZYUVOATZSGJY-UHFFFAOYSA-N

InChi Code

InChI=1S/C6HBr4N3/c7-1-2(8)4(10)6-5(3(1)9)11-13-12-6/h(H,11,12,13)

SMILES Code

BrC1=C(NN=N2)C2=C(Br)C(Br)=C1Br

Appearance

White solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 434.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Winston GM, Nilchian P, Greenfield JP, Jones D. Intrathecal baclofen pump for severe hypertonia in a patient with juvenile Huntington's disease: illustrative case. J Neurosurg Case Lessons. 2024 Dec 2;8(23):CASE24512. doi: 10.3171/CASE24512. PMID: 39622045; PMCID: PMC11616147. 2: Vadlamani N, Ibrahimli S, Khan FA, Castillo JA, Amaravadi KSS, Nalisetty P, Khan S. Efficacy and Safety of Tetrabenazine in Reducing Chorea and Improving Motor Function in Individuals With Huntington's Disease: A Systematic Review. Cureus. 2024 Oct 14;16(10):e71476. doi: 10.7759/cureus.71476. PMID: 39544557; PMCID: PMC11560395. 3: Kane M. Valbenazine Therapy and CYP2D6 Genotype. 2024 Nov 13. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 39565887. 4: Funcis A, Ravera B, Zinzi P, Solito M, Petracca M, Calabresi P, Bentivoglio AR. Neuroleptic malignant syndrome in Huntington disease. Eur J Neurol. 2024 Dec;31(12):e16442. doi: 10.1111/ene.16442. Epub 2024 Oct 23. PMID: 39444167; PMCID: PMC11554869. 5: Olivares-García R, López-Cruz L, Carratalá-Ros C, Matas-Navarro P, Salamone JD, Correa M. Mild forced exercise in young mice prevents anergia induced by dopamine depletion in late adulthood: Relation to CDNF and DARPP-32 phosphorylation patterns in nucleus accumbens. Neuropharmacology. 2025 Jan 1;262:110197. doi: 10.1016/j.neuropharm.2024.110197. Epub 2024 Oct 21. PMID: 39442910. 6: Tripathi S, Sharma Y, Kumar D. Exploring the Role of Deutetrabenazine in the Treatment of Chorea Linked with Huntington's Disease. Curr Rev Clin Exp Pharmacol. 2024 Oct 15. doi: 10.2174/0127724328312991241001051813. Epub ahead of print. PMID: 39415318. 7: Zhu J, Cirincione AB, Strauss MJ, Davis SE, Eans SO, Tribbitt DK, Alshakhshir N, McLaughlin JP. Impact of HIV-1 tat protein on methamphetamine-induced inhibition of vesicular monoamine transporter2-mediated dopamine transport and methamphetamine conditioned place preference in HIV-1 tat transgenic mice. Eur J Pharmacol. 2024 Dec 5;984:177030. doi: 10.1016/j.ejphar.2024.177030. Epub 2024 Oct 2. PMID: 39366503; PMCID: PMC11563864. 8: Tod P, Varga A, Román V, Lendvai B, Pálkovács R, Sperlágh B, Vizi ES. Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue. Br J Pharmacol. 2024 Dec;181(24):5094-5109. doi: 10.1111/bph.17348. Epub 2024 Sep 20. PMID: 39304979. 9: Nilofar F, Ganapathy G, Bose S, V V. Unraveling Diabetic Striatopathy: Clinical and Imaging Perspectives. Cureus. 2024 Aug 18;16(8):e67105. doi: 10.7759/cureus.67105. PMID: 39290934; PMCID: PMC11407699. 10: Im D, Jormakka M, Juge N, Kishikawa JI, Kato T, Sugita Y, Noda T, Uemura T, Shiimura Y, Miyaji T, Asada H, Iwata S. Neurotransmitter recognition by human vesicular monoamine transporter 2. Nat Commun. 2024 Sep 16;15(1):7661. doi: 10.1038/s41467-024-51960-z. PMID: 39284862; PMCID: PMC11405867. 11: Rosano C, Chahine LM, Gay EL, Coen PM, Bohnen NI, Studenski SA, LoPresti B, Rosso AL, Huppert T, Newman AB, Royse SK, Kritchevsky SB, Glynn NW. Higher Striatal Dopamine is Related With Lower Physical Performance Fatigability in Community-Dwelling Older Adults. J Gerontol A Biol Sci Med Sci. 2024 Nov 1;79(11):glae209. doi: 10.1093/gerona/glae209. PMID: 39208421; PMCID: PMC11447735. 12: Gadkari C, Ilyas WM, Pundkar A, Seram RD, Koshy P, Patel A. Unraveling Nonketotic Hyperglycemia Hemichorea-Hemiballismus Syndrome: A Case Report of Diagnosis and Management. Cureus. 2024 Jul 22;16(7):e65094. doi: 10.7759/cureus.65094. PMID: 39171042; PMCID: PMC11338668. 13: Wu M, Ren C, Mao C, Dong L, Li B, Yang X, Huang Z, Zhang H, Li Y, Yan M, Ge Q, Wu R, Feng F, Cui M, Gao J, Huo L. Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification. Neuroimage. 2024 Sep;298:120779. doi: 10.1016/j.neuroimage.2024.120779. Epub 2024 Aug 8. PMID: 39122059. 14: Huang C, Zhang L, Tang T, Wang H, Jiang Y, Ren H, Zhang Y, Fang J, Zhang W, Jia X, You S, Qin B. Application of Directed Evolution and Machine Learning to Enhance the Diastereoselectivity of Ketoreductase for Dihydrotetrabenazine Synthesis. JACS Au. 2024 Jun 26;4(7):2547-2556. doi: 10.1021/jacsau.4c00284. PMID: 39055154; PMCID: PMC11267543. 15: Nguyen HQ, Kuan HS, Crass RL, Quinlan L, Chapel S, Kim K, Brar S, Loewen G. A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia. J Clin Pharmacol. 2024 Nov;64(11):1456-1465. doi: 10.1002/jcph.2498. Epub 2024 Jul 25. PMID: 39051716. 16: Moondra P, Jimenez-Shahed J. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington's disease. Expert Rev Neurother. 2024 Sep;24(9):849-863. doi: 10.1080/14737175.2024.2376107. Epub 2024 Jul 9. PMID: 38982802. 17: Ismail O, Albdour K, Jaber Y, Jaber K, Alsaras A. Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2024 Oct;80(10):1471-1482. doi: 10.1007/s00228-024-03722-5. Epub 2024 Jul 6. PMID: 38969949. 18: Mendonça MD, Barahona-Corrêa JB. Tetrabenazine-induced acute dystonic reaction during the treatment of comorbid tics in a young woman with autism spectrum disorder. Psychiatry Clin Neurosci. 2024 Sep;78(9):558-559. doi: 10.1111/pcn.13705. Epub 2024 Jun 28. PMID: 38938128. 19: Domínguez Carral J, Reinhard C, Ebrahimi-Fakhari D, Dorison N, Galosi S, Garone G, Malenica M, Ravelli C, Serdaroglu E, van de Pol LA, Koy A, Leuzzi V, Roubertie A, Lin JP, Doummar D, Cif L, Ortigoza-Escobar JD. Dyskinetic crisis in GNAO1-related disorders: clinical perspectives and management strategies. Front Neurol. 2024 Jun 6;15:1403815. doi: 10.3389/fneur.2024.1403815. PMID: 38903163; PMCID: PMC11188927. 20: Zhang Y, Jia X, Shi X, Chen Y, Xue M, Shen G, Wen L, Qiao Y, Yang Y. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system. Gen Hosp Psychiatry. 2024 Sep-Oct;90:22-29. doi: 10.1016/j.genhosppsych.2024.06.005. Epub 2024 Jun 12. PMID: 38901166.